EntryPoint Capital’s Pulmonx LUNG Stock Holding History

EntryPoint Capital’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,149	Closed	-$92.4K	–	865
2024 Q3	$92.4K	Buy	+11,149	New	+$80.7K	0.05%	560
2024 Q2	–	Sell	-11,013	Closed	-$102K	–	1309
2024 Q1	$102K	Buy	+11,013	New	+$129K	0.09%	406

Other funds holding LUNG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

EntryPoint Capital's LUNG Position: Q4 2024 in Review

EntryPoint Capital sold out of Pulmonx (LUNG) in Q4 2024, closing a stake of 11,149 shares — an estimated $92.4K sold.

EntryPoint Capital first reported a position in LUNG in Q1 2024 and held it in 2 quarters. The position peaked at $102K in Q1 2024. 118 funds tracked by Wall St. Rank hold LUNG as of Q4 2024.

EntryPoint Capital reported no remaining Pulmonx position as of Q4 2024 after selling out during the quarter.
EntryPoint Capital sold 11,149 Pulmonx shares in Q4 2024, an estimated $92.4K.
EntryPoint Capital first reported a position in Pulmonx in Q1 2024 and held it in 2 quarters.
EntryPoint Capital's Pulmonx position peaked at $102K in Q1 2024.
118 funds tracked by Wall St. Rank held Pulmonx as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.